Cambridge, MA | Nov 2023
Clear Scientific, a clinical-stage biopharmaceutical company, today announced a $12M award from the National Institute on Drug Abuse of the NIH to support development of CS-1103, an antidote for methamphetamine overdose, through Phase 2 clinical trials. This is the first step in our development of a broad-spectrum antidote for illicit and prescription stimulants. Stimulant misuse is a major worldwide public health crisis for which there are no FDA-approved therapeutics.
In particular, meth is the fastest growing drug of abuse in the world, with over 800,000 annual emergency department visits and more than 37,000 deaths per year in the US alone, greater than 30% of all fatal drug overdoses, at a cost to the US hospital system of $8B. Deaths due to meth overdose have increased 14-fold since 2015.
“We are grateful for NIDA’s continued support in bringing this urgently needed treatment to patients,” said Shekar Shetty, Clear Scientific’s Chief Executive Officer.
CS-1103 is a novel sequestrant-based therapeutic that immediately inactivates target intoxicants by binding and encapsulation, rapidly reversing their toxic effects. CS-1103 also accelerates clearance of targets from plasma into urine, performing rapid detoxification of the patient; “Remove the Cause, Remove the Effect.” CS-1103 is currently in Phase 1 Clinical Trials.
About Clear Scientific
Clear Scientific is a Cambridge, MA-based clinical stage biopharmaceutical company pioneering novel therapies for life-threatening and debilitating conditions caused by an excess of harmful substances in the body. The founding team includes Prof. George Whitesides (Harvard University), who pioneered the development of sequestrant-based therapeutics. The company has a strong patent estate licensed from Massachusetts General Hospital and University of Maryland.
For more information, visit https://www.clearsci.com.